Recruiting

Observational Study

Sponsor:

University of Virginia

Code:

NCT03706768

Conditions

Aneurysmal Subarachnoid Hemorrhage

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Glycocalyx

Study Details

Brief summary:

This study will provide novel information to the literature base for the pathophysiology of aneurysmal subarachnoid hemorrhage. The association of breakdown products in the serum of aSAH patients were reported in a very small case series of 3 patients, as mentioned above. However, while their results are intriguing and encouraging, our study will provide more definitive information about the GC in aSAH. If there is a positive correlation, the results of this study will guide future investigations into new therapies for this devastating disease such as MMP inhibition with doxycycline.

Conditions

Aneurysmal Subarachnoid Hemorrhage

Study ID

NCT03706768

Start date

May 1, 2018

Status verified date

Apr, 2019

Completion date

May 1, 2020

Anticipated

Primary completion date

May 1, 2020

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • • Age 18 years of age and older

  • Cerebral aneurysm on CT-angio

Exclusion Criteria:

  • • comfort care only orders,

  • the absence of an aneurysm on CT-angiography,
  • onset of aneurysm rupture > 24 hours,
  • and inability to obtain informed consent from patient or family pregnant women

Study Design

Enrollment

42 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

other: Glycocalyx

degree of glycocalyx breakdown in patients with aSAH

Interventions

Glycocalyx

Measure Degradation of the Glycocalyx

Primary outcome measure

  • Syndecan-1 and heparin sulfate [ Time Frame: day 0 through day 13 ]

Central Contacts and Locations

Central contacts

Marcia E Birk

434-924-2283meb2w@virginia.edu

Locations

University of Virginia Health System

Recruiting

Charlottesville, Virginia, United States, 22908

More Information

Sponsor

University of Virginia

Last update posted

Apr 25, 2019

Last verified

Apr, 2019

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Virginia on 2019-04-25.